Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Maintenance in CTCL Post-Transplant
NCT07178457Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2025
- Primary completion
- Nov 2032
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of brentuximab vedotin in cutaneous T-cell lymphoma (CTCL), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07178457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178457.